Hoelzer, Dieter and Walewski, Jan and Doehner, Hartmut and Viardot, Andreas and Hiddemann, Wolfgang and Spiekermann, Karsten and Serve, Hubert and Duehrsen, Ulrich and Huettmann, Andreas and Thiel, Eckhard and Dengler, Jolanta and Kneba, Michael and Schaich, Markus and Schmidt-Wolf, Ingo G. H. and Beck, Joachim and Hertenstein, Bernd and Reichle, Albrecht and Domanska-Czyz, Katarzyna and Fietkau, Rainer and Horst, Heinz-August and Rieder, Harald and Schwartz, Stefan and Burmeister, Thomas and Goekbuget, Nicola (2014) Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. BLOOD, 124 (26). pp. 3870-3879. ISSN 0006-4971, 1528-0020
Full text not available from this repository. (Request a copy)Abstract
This largest prospective multicenter trial for adult patients with Burkitt lymphoma/leukemia aimed to prove the efficacy and feasibility of short-intensive chemotherapy combined with the anti-CD20 antibody rituximab. From 2002 to 2011, 363 patients 16 to 85 years old were recruited in 98 centers. Treatment consisted of 6 5-day chemotherapy cycles with high-dose methotrexate, high-dose cytosine arabinoside, cyclophosphamide, etoposide, ifosphamide, corticosteroids, and triple intrathecal therapy. Patients >55 years old received a reduced regimen. Rituximab was given before each cycle and twice as maintenance, for a total of 8 doses. The rate of complete remission was 88% (319/363); overall survival (OS) at 5 years, 80%; and progression-free survival, 71%; with significant difference between adolescents, adults, and elderly patients (OS rate of 90%, 84%, and 62%, respectively). Full treatment could be applied in 86% of the patients. The most important prognostic factors were International Prognostic Index (IPI) score (0-2 vs 3-5; P=.0005), age-adjusted IPI score (0-1 vs 2-3; P=.0001), and gender (male vs female; P=.004). The high cure rate in this prospective trial with a substantial number of participating hospitals demonstrates the efficacy and feasibility of chemoimmunotherapy, even in elderly patients. This trial was registered at www.clinicaltrials.gov as #NCT00199082.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; HIGH-DOSE METHOTREXATE; NON-HODGKINS-LYMPHOMA; CODOX-M/IVAC; CELL LYMPHOMA; GROUP-B; CHILDREN; SURVIVAL; THERAPY; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 05 Aug 2019 09:09 |
| Last Modified: | 05 Aug 2019 09:09 |
| URI: | https://pred.uni-regensburg.de/id/eprint/9042 |
Actions (login required)
 |
View Item |
